Trials / Completed
CompletedNCT00962065
Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX4211 in Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LX4211 Low Dose | A low dose of LX4211; daily oral intake for 28 days |
| DRUG | LX4211 High Dose | A high dose of LX4211; daily oral intake for 28 days |
| DRUG | Placebo | Matching placebo dosing with daily oral intake for 28 days |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2009-12-01
- First posted
- 2009-08-19
- Last updated
- 2011-03-03
- Results posted
- 2011-03-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00962065. Inclusion in this directory is not an endorsement.